Cancer Therapy: Monoclonal Antibodies, Lymphokines New Developments in Surgical Oncology and Chemo- and Hormonal Therapy PDF
Preview Cancer Therapy: Monoclonal Antibodies, Lymphokines New Developments in Surgical Oncology and Chemo- and Hormonal Therapy
H. G. Beger M. Buchler R. A. Reisfeld G. Schulz (Eds.) Cancer Therapy Monoclonal Antibodies, Lymphokines New Developrrzents in Surgical Oncology and Chemo- and Hormonal Therapy With the Editorial Collaboration of B. Greifenberg, Marburg and K. H. Link, VIm With 94 Figures and 92 Tables Springer-Verlag Berlin Heidelberg New York London Paris Tokyo Dr. Hans G.Beger, FACS Professor of Surgery Dr. Markus Buchler Lecturer in Surgery Department of General Surgery University of Ulm SteinhOvelstraI3e 9, 7900 Ulm, FRG Dr. Ralph A. Reisfeld Division of Tumor Cell Biology Scripps Clinic & Research Foundation 10666 North Torrey Pines Road, La Jolla, CA 92037, USA Priv. Doz. Dr. Gregor Schulz Clinical Research Behringwerke AG Marburg P.O. Box 1140, 3550 Marburg, FRG ISBN-13:978-3-642-73723-7 e-ISBN-13:978-3-642-73721-3 DOl: 10.1007/978-3-642-73721-3 Library of Congress Cataloging·in·Publication Data Cancer therapy : monoclonal antibodies, Iymphokines : new developments in surgical oncology and chemo· and hormonal therapy 1 H.G.Beger ... let aL], (eds.) ; in collaboration with B. Greifenberg. p. em. Includes bibliographies and index. ISBN-I3:978-3-642-73723-7 (U. S.) 1. Cancer--Treatment. 2. Antibodies, Monoclonal--Therapeutic use. 3. Lymphokines--Thera- peutic use. 4.Cancer--Surgery. 5.Cancer--Hormone therapy. 6.Cancer--Chemotherapy. 7.Beger, H.G. (Hans G.) I. Greifenberg, B. IDNLM: 1. Antibodies, Monoclonal--therapeutic use. 2. Antineoplastic Agents--therapeutic use. 3. Hormones-therapeutic use. 4. Lymphokines--therapeutic use. 5. Neoplasms--drug therapy. 6. Neoplasms--surgery. QZ 266 C2172] RC270.8.C373 1988 616.99'406--dc19 DNLM/DLC 88-29509 This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. Duplication of this publication or parts thereof is only permitted under the provisions of the German Copyright Law of September 9, 1965, in its version of June 24, 1985, and a copyright fee must always be paid. Violations fall under the prosecution act of the German Copyright Law. © Springer-Verlag Berlin Heidelberg 1989 Softcover reprint of the hardcover 1st edition 1989 The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. Product Liability: The publisher can give no guarantee for information about drug dosage and application thereof contained in the book. In every individual case the respective user must check its accuracy by consulting other pharmaceutical literature. 2125/3140-543210 - Printed on acid-free paper. Preface The recent development of new strategies in cancer therapy was the main topic of an international meeting which took place at Rei- sensburg Castle in February, 1988. Here, experts in the field of tu- mor immunology, surgical oncology, and cancer chemotherapy dis- cussed future directions in cancer treatment. In 1975, Kohler and Milstein first described the technique of cell hybridization, which is used to produce monoclonal antibody (MoAb) reagents for the detection of tumor markers in sera, the in vitro analysis of leukemia or the histologic differential diagnosis of malignancies as opposed to chronic infectious diseases. Recently, it has been demonstrated that radiolabelled murine MoAbs are ex- cellent tools for the in vivo localization of tumors. Meanwhile, ini- tial clinical experience with the therapeutical use of MoAbs has been gained which shows that the latter either mediate cytotoxic functions, such as antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, or are effective in conjugation with radionuclides, cytostatics, or toxins. New modifications, such as the "humanization" of murine antibodies, which will improve the efficacy of the above-mentioned therapy, are discussed in this volume. Recent advances in DNA technology have resulted in the produc- tion of a number of recombinant glycoproteins, for example, in- terferons or tumor necrosis factor, which directly inhibit tumor growth. Other immune response modifiers, such as interleukin-2 (IL-2) or the colony-stimulating factors (CSFs), which are able to enhance proliferation and activity of T-Iymphocytes or other he- matopoietic cells, are now clinically available. Stimulated "killer lymphocytes" or macrophages are powerful "tumor killers", as has been demonstrated by clinical studies using recombinant IL-2, GM-CSF, or G-CSF. In addition, hematopoietic growth factors are able to accelerate regeneration of blood cells following chemother- apy. Initial clinical experience with GM-CSF and G-CSF has shown that severe neutropenia may be prevented or at least decel- erated, which then results in a reduced number of severe infec- tions. Other CSFs, such as interleukin 3 or erythropoietin, induce speedier reconstitution of platelets or erythrocytes. Thus, the clini- cal application of recombinant hematopoietic growth factors will VI Preface not only improve tolerability of chemotherapy, but may also allow the administration of higher doses of cytostatics, thus resulting in better response rates. The approach of regional chemotherapy combined with new tech- niques of surgical oncology, including isolated regional hyperther- mal perfusion and chemoembolization of tumors, presents a new concept of cancer treatment. Several randomized trials now exist which demonstrate a higher response rate following intrahepatic infusion rather than systemic infusion in the treatment of hepatic metastases from colorectal carcinoma. The results of regional chemotherapy of the liver from different research institutions are presented in this volume, the success rates pointing to the promis- ing role of regional cancer treatment in the future. In some malignancies, e. g., lymphoblastic leukemia, testicular can- cer, and Hodgkin's disease, a high frequency of long-term cure rates has been achieved by the introduction of new chemothera- peutic regimens. However, patients with some of the most common cancers, for instance, lung cancer, colorectal cancer, or pancreatic cancer, still have a poor chance of survival if the tumor cannot be removed by surgery. We hope that the various new strategies in cancer treatment pre- sented in this book will help to point out that only combined re- search efforts in various fields of cancer treatment will result in im- proved therapy of malignancies. December 1988 H. G. Beger M. Buchler R. A. Reisfeld G. Schulz Contents Monoclonal Antibodies ........... . 1 R. A. REISFELD, B. MULLER, and H.-M. YANG Immunochemotherapy of Cancer: A Perspective 3 K. BOSSLET, A. STEINSTRASSER, A. SCHWARZ, H. P. HARTH US, G. LUBEN, L. KUHLMANN, and H. H. SEDLACEK Quantitative Considerations Supporting the Irrelevance of Circulating Serum Carcinoembryonic Antigen for the Immunoscintigraphic Visualization of Carcinoembryonic Antigen-Expressing Carcinomas . . . . . . . . . . . . . . . 10 H.KALOFONOS and A.A. EPENETOS Radioimmunotherapy with Iodine 131-Labelled Antibodies in Ovarian, Colonic and Brain Tumours . . . . . . . . . . . .. 18 A. PLANTING, J. VERWEIJ, P. COX, M. PILLA Y, and G. STOTER Radioimmunodetection and Radioimmunotherapy in Myosarcoma . . . . . . . . . . . . . . . . . . . . . . . . 27 M.BUCHLER, R.KUBEL, R.KLAPDOR, K.-H.MUHRER, H. FRIESS, B. LORENZ, G. SCHULZ, K. BOSSLET, and H. G. BEGER Immunotherapy of Pancreatic Cancer with Monoclonal Antibody BW 494: Results from a Multicentric Phase I-II Trial. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 32 H. MELLSTEDT, J.-E. FRODIN, G. MASUCCI, C. LINDEMALM, C. WEDELIN, B. CHRISTENSSON, J. SHETYE, P. BIBERFELD, A.-K. LEFVERT, P. PIHLSTEDT, J. MAKOWER, U. HARMENBERG, B. WAHREN, B. AHLMAN, B. CEDERMARK, R. ERWALD, I. MAGNUSSON, J.NATHANSSON, and A.RIEGER Mab 17-1 A Used for Therapy of Patients with Metastatic Colorectal Carcinomas . . . . . . . . . . . . . . . . . . .. 42 W. G. DIPPOLD and K.-H. MEYER ZUM BUSCHENFELDE Immunotherapy of Malignant Melanomas ........... 51 R.KLAPDOR Interaction of Monoclonal Antibodies with Biological Response Modifiers and Cytostatics . . . . . . . . . . . . . ., 56 VIII Contents Lymphokines . . .. 71 A.LINDEMANN, F.HERRMANN, H.GAMM, W.OSTER, and R. MERTELSMANN Cancer Treatment with Cytokines: Concepts and First Clinical Experience . . . . . . . . . . . . . . . . . . . . . . . . . . .. 73 M. S. MITCHELL Low-dose Cyclophosphamide and IL-2 in the Treatment of Advanced Melanoma . . . . . . . . . . . . . . . . . . . 85 A.GANSER, B.VOLKERS, J.GREHER, F.WALTHER, and D.HOELZER Application of Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Malignant Hematological Diseases 90 H. LINK, M. FREUND, H. KIRCHNER, M. STOLL, H. SCHMID, P. BUCSKY, J. SEIDEL, G. SCHULZ, R. E. SCHMIDT, H. RIEHM, H. POLIWODA, and K. WELTE Enhancement of Autologous Bone Marrow Transplantation with Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) ........ . 96 R.G.STEIS, J.CLARK, D.L.LONGO, J.SMITH, R.MILLER, F. RUSCETTI, J. HURSEY, and W. URBA A Phase Ib Evaluation of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor ..... 103 N. NIEDERLE and G. KUMMER The Role of Interferon in the Management of Patients with Hairy Cell Leukemia and Multiple Myeloma . . . . . . 112 F.PORZSOLT, W.DIGEL, C.BUCK, A.RAGHAVACHAR, M.STEFANIC, and W.SCHONIGER Possible Mechanism of Interferon Action in Hairy Cell Leukemia. . . . . . . . . . . . . . . . . . . . . . . . . .. . 124 R. SCHIESSEL Tumor Vaccination in the Treatment of Colorectal Cancer. . 132 New Approaches in Surgical Oncology .............. 141 R.BITTNER and H.G.BEGER New Developments in Surgical Oncology . . 143 P.SCHLAG Cancer Surgery - Conservative or Radical? . . 154 S.BENGMARK Regional Chemotherapy of the Liver and Hepatic Artery Occlusion .............................. 163 Contents IX N.KEMENY Regional Chemotherapy of Hepatic Metastases. 169 F. SAFI, R. BITTNER, R. ROSCHER, K. SCHUMACHER, W. GAUS, and H.G.BEGER Regional Chemotherapy in Hepatic Metastases of Colorectal Carcinoma: Continuous Intra-arterial Versus Continuous Intra-arterial/Intravenous Therapy ............... 176 K.-H.MUHRER and H.GRIMM Isolated Regional Hyperthermal Liver Perfusion: Indications, Technique and Results ...................... 190 K.-H. SCHULTHEIS, M. PLIESS, H.-H. GENTSCH, H. BODEKER, C.GEBHARDT, and K.SCHWEMMLE Chemoembolization of Liver Tumors .............. 201 S.G.BOWN New Cancer Treatment with Lasers - Photodynamic Therapy and Interstitial Hyperthermia ................... 216 E. KRAAS, E. LOHDE, O. ABRI, H. SCHLICKER, S. MATZKU, H.KALTHOFF, and W.H.SCHMIEGEL Specificity, Kinetics, and Distribution of Monoclonal Antibodies to Carcinoembryonic Antigen in Human Colorectal Carcinoma by Ex Vivo Human Tumor Perfusion. . 223 Chemotherapy and Hormonal Therapy . . . . . . . . . . . . . . 233 G.FALKSON Chemotherapy: Benefits and Limits . 235 H. P. KRAEMER and H. H. SEDLACEK The Human Tumor Clonogenic Assay for the Prediction of Tumor Sensitivity ......................... 243 K.H.LINK Chemosensitivity: Directed Regional Chemotherapy of Liver Metastases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 249 I. H. KRAKOFF Clinical Development of New Anthracyclines . 259 J.VERWEIJ, E.SALEWSKI, and G.STOTER First Clinical Experience with Cytorhodin S - The First Compound of a New Class of Anthracyclines. . . . . . . . . . 263 B. GREIFENBERG Pirarubicin: A New Drug in the Treatment of Malignant Diseases ........................... .. 270 H.-H. FIEBIG, H. HENSS and H. ARNOLD Pirarubicin - A New Anthracycline with High Activity in Untreated Patients with Small-Cell Cancer of the Lung . . . . 280 X Contents K.HOFFKEN New Approaches in the Hormonal Therapy of Breast Cancer . 284 E. D. KREUSER, W. D. HETZEL, F. PORZSOLT, and R. HAUTMANN Reproductive Toxicity with and Without Administration of Luteinizing-Hormone-Releasing Hormone Agonist During Adjuvant Chemotherapy in Patients with Germ Cell Tumors . 292 Subject Index ........................... 303 List of Contributors * Abri, O. 2231 Harmenberg, U. 42 Ahlman, B. 42 Hautmann, R. 292 Arnold, H. 280 Harthus, H.P. 10 Beger, H.G. 32,143, 176 Herrmann, F. 73 Bengmark, S. 163 Hetzel, W. D. 292 Biberfeld, P. 42 Henss, H. 280 Bittner, R. 143, 176 HOffken, K. 284 BOdeker, H. 201 Hoelzer, D. 90 Bosslet, K. 10,32 Hursey, J. 103 Bown, S.G. 216 Kalofonos, H. 18 Buck, C. 124 Kalthoff, H. 223 Bucsky, P. 96 Kemeny, N. 169 Buchler, M. 32 Kirchner, H. 96 Cedermark, B. 42 Klapdor, R. 32, 56 Christensson, B. 42 Kraas, E. 223 Clark, J. 103 Kraemer, H. P. 243 Cox, P. 27 Krakoff, I. H. 259 Digel, W. 124 Kreuser, E. D. 292 Dippold, W. G. 51 Kubel, R 32 Epenetos, AA 18 Kuhlmann, L. 10 Erwald, R. 42 Kummer, G. 112 Falkson, G. 235 Lefvert, A-K. 42 Fiebig, H.-H. 280 Lindemalm, C. 42 Freund, M. 96 Lindemann, A 73 Friess, H. 32 Link, H. 96 FrOdin, J.-E. 42 Link, K. H. 249 Gamm, H. 73 LOhde, E. 223 Gaus, W. 176 Longo, D.L. 103 Ganser, A 90 Lorenz, B. 32 Gebhardt, C. 201 Luben, G. 10 Gentsch, H.-H. 201 Magnusson, I. 42 Greher, J. 90 Makower, J. 42 Greifenberg, B. 270 Masucci, G. 42 Grimm, H. 190 Matzku, S. 223 * You will find the addresses at the beginning of the respective contribution. 1 Page on which contribution begins.
The list of books you might like
